Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths in the world. In the United States it is the third most commonly diagnosed cancer and is the second leading cause of cancer-related deaths. The growth and progression of colon polyps and cancers, as well as other solid tumors, requires angiogenesisthe formation of new blood vessels from pre-existing vessels [1, 2] . Vascular endothelial growth factor A (referred here to as VEGF), identified, cloned and named by N. Ferrara [3, 4] , is one of the most potent factors that promote tumor angiogenesis [1, 2, [5] [6] [7] [8] . VEGF triggers angiogenesis by inducing endothelial cell growth, migration, and tube formation [5, 9] .
VEGF is expressed in various cells including myofibroblasts, fibroblasts and endothelial cells in normal tissues, and plays a role in the physiological angiogenesis such as that required for tissue injury healing [1, 9, 10] . VEGF is also highly expressed by most human cancers (e.g., breast, ovarian, colon, pancreatic and esophageal cancer) and its expression often correlates with tumor progression and poor prognosis [11] [12] [13] [14] [15] [16] [17] . Several studies have demonstrated the critical requirement of VEGF for tumor angiogenesis and growth [18] [19] [20] . Kondo Abbreviations: CRC, colorectal cancer;°C, degrees centigrade; h, hours; HCT116, colon cancer cell line; HT29, colon cancer cell line; lM, micro molar; ll, micro liter; mm, millimeter; mM, millimolar; mRNA, messenger ribonucleic acid; nm, nanometer; NCM356, normal colonic mucosal epithelial cells; NCM460, normal colonic mucosal epithelial cells; RT-PCR, reverse transcription and polymerase chain reaction; VEGF, vascular endothelial growth factor; VEGF-R1, vascular endothelial growth factor receptor 1; VEGF-R2, vascular endothelial growth factor receptor 2.
gene formed faster-growing tumors with increased vascularity compared to xenografts of cells transfected with a control vector [18] . Furthermore, Yuan et al., showed that treatment with VEGF neutralizing antibody reduced vascular permeability, vessel diameter and vessel volume in xenografts of human colon adenocarcinoma cells in SCID mice [19] . The first anti-VEGF drug, bevacizumab (a humanized monoclonal antibody against VEGF) was approved for colon cancer treatment in 2004 [20] . It binds directly to VEGF to form a protein complex, which is incapable of binding to VEGF receptor sites. Bevacizumab blocks the growth of new blood vessels to tumors and can extend survival in some patients with metastatic colorectal cancer [20] .
All of these studies support the role of VEGF in the induction of tumor angiogenesis that promotes tumor growth by enhanced vascularization. However, the extent to which VEGF can directly affect cancer cell growth independently of its angiogenic properties is not fully known. Furthermore, the presence of VEGF and its receptors in colon cancer cells has not been clearly described and remains controversial. A study of 131 colonic adenocarcinoma patients showed that in 86 patients (66%), the tumors did not express VEGF [21] . Another study of 259 formalin-fixed and paraffin-embedded specimens from sequential patients with colorectal cancer showed that 63.3% (138 of 259) of the specimens did not express VEGF in the tumor cells [22] . Warren et al., examined 30 metastases of human colorectal cancer to liver in a mouse model and showed that VEGF-R1 and VEGF-R2 mRNA expression was limited predominantly to endothelial cells of the tumors [23] . Calvani et al., suggested that different colon cancer cells can differentially express VEGFR-2 [24] . These studies taken together indicate that presence of VEGF and its receptors in colon cancer cells has not been established conclusively, and constitutes a significant gap in our knowledge of colon cancer.
Our present study examined the expression of VEGF and its receptors in human colon cancer specimens À normal and colon cancer tissue arrays; and, in cultured human colon cancer cell lines. We present evidence that: (a) normal colonic epithelial cells do not generate VEGF or express its receptors; (b) VEGF and its receptors are expressed in colon cancer cells; and furthermore VEGF directly promotes colon cancer cell proliferation independently of its primary role as a pro-angiogenic factor.
Materials and methods

Tissue microarray
The use of de-identified commercial human colonic mucosal biopsy specimens for immunostaining was approved by the Institutional review Board at Veterans Affairs Long Beach Healthcare System. Three colon tissue microarrays (TMA; CC05-02-001, CS05-01-001-035 and NC05-01) containing de-identified human colon adenocarcinoma and normal tissue specimens were purchased from Cybrdi Inc., Rockville, MD. CC05-02-001 TMA has 18 matched pairs of human colon adenocarcinomas, tumor margin area and normal colon tissues. CS05-01-001-035 TMA has 22 adenocarcinoma and 3 normal colon specimens. NC05-01 TMA has 3 adenocarcinoma and 20 normal colon specimens.
Cell culture
Two human colorectal cancer (CRC) cell lines À HCT116 and HT29 (American Type Culture Collection, Manassas, VA) were used. As controls, 2 normal human colonic epithelial cell lines, NCM356 and NCM460 (INCELL Corporation, San Antonio, TX) were used. NCM356 and NCM460 cell lines were obtained by a materials transfer agreement with INCELL Corporation, San Antonio, TX. Cells were cultured in recommended growth media and cultures were synchronized by serum starving for 18 h prior to all experiments.
Immunostaining for VEGF and its receptors
Tissue microarrays of paraffin-embedded sections were deparaffinized and immunostained with specific antibodies for VEGF (sc-507, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), VEGF-R1 (sc-316, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and VEGF-R2 (sc-504, 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA and visualized using Alexa Fluor dye 568 anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA, USA) using similar methods as described in our previous study [25] . Immunofluorescence was evaluated independently by two investigators (blinded to the microarray coding scheme) using a Nikon Optiphot microscope with epifluorescence. The expression of VEGF, VEGF-R1 and VEGF-R2 in colon cancer cells was graded on a scale from 1+ to 3+. In addition, five fields were randomly selected and staining signal intensity was quantified using MetaMorph 7.0 (Molecular Devices, Downington, PA, USA). The expression and localization of VEGF and its receptors in cultured human normal colonic mucosal epithelial cells and in human colorectal cell lines was examined by immunostaining using the above listed antibodies for VEGF, VEGF-R1 and VEGF-R2, Alexa Fluor dye 488 anti-rabbit secondary antibody and methods described previously [26] . The staining signal intensity was quantified using MetaMorph 7.0 (Molecular Devices, Downington, PA, USA) and expressed as arbitrary units.
Determination of VEGF secreted by CRC cells into culture media using enzyme-linked immunosorbent assay (ELISA)
CRC cell lines and normal colonic epithelial cells were cultured in equal density in 12-well plates in complete growth medium overnight. Wells were washed with PBS and cells were cultured in reduced (1%) serum growth media for 6, 24 and 48 h. Cell culture media was removed at each time point, cell debris were removed by centrifugation and cell culture supernatants were frozen for use in the ELISA. The concentration of VEGF in the cell culture supernatants was measured using the human VEGF immunoassay Quantikine ELISA kit (R&D systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Briefly, 200 ll of culture supernatants were added to the wells of a microplate pre-coated with VEGF antibody and incubated for 2 h at room temperature. The plates were then incubated with anti-human VEGFÀHRP conjugate at room temperature for 2 h. A color reaction was induced by the addition of premixed TMB substrate solution and was stopped 30 min later by the addition of a stop solution. The absorbance was measured on an ELISA plate reader at 450 nm.
Determination of VEGF mRNA by reverse transcription real-time quantitative polymerase chain reaction (PCR)
Total cellular RNA was isolated from normal colonic mucosal epithelial cells and CRC cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Total RNA (1 lg) was treated with deoxyribonuclease I and reverse transcribed using the GeneAmp RNA-PCR kit (Applied Biosystems, Foster City, CA, USA) as described in our previous studies [27, 28] . The mRNA levels of VEGF and b-actin were quantified by real-time PCR using pre-validated QuantiTect assays (Qiagen, Valencia, CA, USA) and the iCycler real-time PCR detection system (Bio-Rad, Hercules, CA, USA). Relative mRNA levels were calculated using the2
ÀDDCt method and b-actin was used as a reference.
Determination of VEGF protein by western blot analysis
Expression of VEGF was determined by western blotting using methods described in our previous studies [26, 29] . Total cellular proteins were isolated from cultured cells in ice-cold radio-immuno-precipitation assay (RIPA) buffer. Protein concentration was determined by standard Bradford assay (Bio-Rad, Hercules, CA, USA). Proteins were subjected to SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were incubated with specific antibodies against VEGF (1:250, Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by peroxidase-conjugated secondary antibodies. Immunoreactive proteins were visualized using ECL detection system. b-actin was used as an internal control reference.
Cell proliferation assay
CRC cells were cultured on glass coverslips and serum starved for 18 h. CRC cell proliferation at baseline was determined by Bromodeoxyuridine (BrdU) assay using the BrdU Cell Proliferation Kit (EMD Millipore Corporation, Billerica, MA) according to the manufacturer's instructions. The total cell count and number of BrdU positive cells were determined. Cell proliferation was expressed as percent of BrdU positive cells.
Statistical analysis
Data are presented as mean ± SD. Statistical significance was analyzed by either Student's T-test or analysis of variance. A p value less than 0.05 was considered statistically significant.
Results
Increased protein expression of VEGF and its receptors VEGF-R1 and VEGF-R2 in human CRC tissue specimens
Immunofluorescence staining for VEGF and its receptors VEGF-R1 and VEGF-R2 was performed in 43 histological specimens of human colorectal cancer (CRC) and 41 normal colonic mucosa. Expression of VEGF, VEGF-R1 and VEGF-R2 was strong (aberrant) in CRC tissues compared to normal colonic mucosa (Fig. 1) . VEGF, VEGF-R1 and VEGF-R2 was localized to CRC cells in CRC tissues (Fig. 1) . Normal colonic mucosa specimens had only minimal staining (comparable to background) for VEGF and its receptors. All human colon cancer tissue specimens stained positive for VEGF and its receptors; 63% of array sections had strong staining (2+ or 3+ on a scale from 1+ to 3+) for VEGF and its receptors in malignant cells, while 37% of the array sections had weak staining (1+ on a scale from 1+ to 3+) for VEGF and its receptors in malignant cells.
CRC cell lines express and secrete VEGF
We examined expression of VEGF mRNA and protein in the human CRC cell lines, HCT116 and HT29, and in normal colonic epithelial NCM356 and NCM460 cells by real time RT-PCR and western blotting. Normal colonic epithelial cell lines expressed no or minimal VEGF mRNA and protein. HCT116 and HT29 CRC cells expressed 13.2-fold and 7-fold higher VEGF mRNA, respectively (both p < 0.01), vs. normal colonic mucosal epithelial cells ( Fig. 2A ). These cells also had 6-fold and 9.8-fold higher VEGF protein expression, respectively (both p < 0.001), vs. normal colonic mucosal epithelial cells (Fig. 2B) .
Next, we quantified the levels of VEGF secreted into culture media by NCM460, HCT116 and HT29 cells over a 48 h period. VEGF was detected in culture medium supernatant of HCT116 cells by ELISA within 6 h and the VEGF levels continued to rise for 48 h (the duration of the study) significantly compared to NCM460, which only secreted very low VEGF amounts, which were undetectable until 24 h of culture (Fig. 2C) .
CRC cells express VEGF-R1 and VEGF-R2
We examined expression of VEGF, VEGF-R1 and VEGF-R2 in HCT116 and HT29, and in normal colonic epithelial NCM460 cells by immunostaining. Protein expression of VEGF and its receptors, VEGF-R1 and VEGF-R2 was strong in CRC cells vs. absent or minimal in normal colonic mucosal epithelial cells (Fig. 3) .
VEGF is critical for colon cancer cell proliferation in vitro
Since our studies demonstrated that colon cancer cells express VEGF and its receptors, we therefore examined the functional consequence of blocking VEGF receptor kinase activity (VEGF signaling) on colon cancer cells proliferation. We inhibited VEGF receptor kinase using AAL993 (2-(Pyridin-4-ylmethylamino)-N-[3-(trifluoromethyl)phenyl]benzamide), a highly specific and potent inhibitor of VEGF-R1 and VEGF-R2 that blocks the downstream action of VEGF signaling [30] . Cells were treated with 1 lM AAL993 or solvent (DMSO) for 4 h and the effect of blocking VEGF function on CRC cell proliferation was examined (n = 3). Blockade of VEGF signaling using the VEGF receptor kinase inhibitor significantly decreased HCT116 and HT29 cells' proliferation by 2.2-fold and 2.7-fold, respectively (both p < 0.001) (Fig. 4) indicating that the proliferation of these cells is partly dependent on VEGF.
Discussion
VEGF plays a critical role in colon cancer growth via angiogenesis (by promoting endothelial cell growth, migration and survival), which is responsible for vascularizing colon tumors and [9, 31, 32] . VEGF is produced by various cell-types including myofibroblasts, endothelial cells, macrophages and transformed cells [9] . Once secreted by these cells, VEGF can act on other cells in a paracrine manner and promote cell survival, migration and differentiation. Whether colon cancer cells secrete VEGF and whether VEGF can directly stimulate the growth of these cells has not been conclusively established. Our present study demonstrated that colon cancer cells secrete VEGF and express VEGF-R1 and VEGF-R2, indicating the possibility that VEGF can directly stimulate growth of colon cancer cells via autocrine signaling.
Several studies have demonstrated that normal colonic epithelium does not express VEGF [21, 22] . Studies investigating the role of VEGF in colon cancer growth have primarily focused on endothelial cells, and its role in the induction of the angiogenesis responsible for vascularizing colon tumors [22, 24, [31] [32] [33] . However, the concept that VEGF can be generated by colon cancer cells remains controversial. Moreover, whether colon cancer cells express VEGF-R1 and VEGF-R2 has not been conclusively established. Fan et al. demonstrated a weak VEGF-R1 expression in eight of ten primary colon cancer specimens and significantly higher VEGF-R1 expression in six of nine metastases of colon cancer to liver examined [34] . In that study, VEGF-R1 was not detectable in normal colonic mucosa. VEGF-R2 immunostaining in colon cancer tissues was shown to be primarily in endothelial cells, while carcinoma cells stained faintly [22, 35] . Calvani et al., suggested that colon cancer cells can differentially express VEGF-R2 based on the different population of the cells within the tumor that they originate from, indicating that there may be a differential responsive of colon cancer cells to VEGF [24] .
Our study showed that CRC cells in colon cancer tissues and cultured CRC cell lines express both VEGF-R1 and VEGF-R2. This study also demonstrated that the inhibition of VEGF receptor kinase using specific inhibitor AAL-993 results in decreased cell proliferation of cultured colon cancer cells. Recently, a VEGF receptor tyrosine kinase inhibitor with activity against all three receptors for VEGF -cediranib, has been proposed for the treatment of metastatic colon cancer and has been shown to have a similar activity to bevacizumab [36] . Our current study indicates a role of VEGF in directly mediating proliferation and growth of colon cancer cells that express VEGF-R1 and VEGF-R2 via an autocrine mechanism in addition to the previously recognized role of VEGF as a potent inducer of cancer angiogenesis. This study may have significant implications À assessment of VEGF and its receptor expression in biopsies can provide additional information whether a particular cancer patient will respond to anti-VEGF treatment. Furthermore, VEGF may perhaps regulate autocrine growth of other non-colonic malignant cells in various tissues. 
